Abstract:
Objective:To compare the difference of Response Evaluation Criteria in Solid Tumors 1. 1 (RECIST 1. 1) and modified Re -sponse Evaluation Criteria in Solid Tumors (mRECIST) in the treatment of hepatocellular carcinoma (HCC) after stereotactic body radio -therapy (SBRT). Methods:From Janurary 2014to August 2015, thirty- five patients with HCC treated with SBRT were included in De -partment of Radiation Oncology and Integrative Oncology of Navy General Hospital of PLA, and SBRT efficacy was evaluated based on RECIST 1. 1 and mRECIST criteria. Results:Under RECIST 1. 1, one patient had complete response (CR), 20had partial response (PR), and 11achieved stable disease (SD) at three months. Three patients had progressive disease (PD). The overall best response rate (CR+PR) was 60%. In comparison, under mRECIST,10patients had CR, 16had PR, and 6 achieved SD at three months. Three patients had PD. The overall best response rate was74. 28%. The statistical analysis showed that Kappa= 0. 402 (χ2=43. 3, P<0. 001 ) was less than 0. 75but greater than0. 4, indicating that it had not reached the two diagnostic criteria of consistency degree of satisfaction. According to the mRECIST criteria, the objective remission group (CR+PR) was superior to the nonobjective remission group (SD+PD) in progression-free survival ( P<0. 001 ). Conclusion: For unresectable HCC, mRECIST may be more useful than RECIST 1. 1 in evaluating HCC response to SBRT.